DK2248815T3 - 3-sulfonyl-pyrazolo[1,5-a]pyrimidiner/antagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelsen deraf - Google Patents
3-sulfonyl-pyrazolo[1,5-a]pyrimidiner/antagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelsen deraf Download PDFInfo
- Publication number
- DK2248815T3 DK2248815T3 DK09703835.0T DK09703835T DK2248815T3 DK 2248815 T3 DK2248815 T3 DK 2248815T3 DK 09703835 T DK09703835 T DK 09703835T DK 2248815 T3 DK2248815 T3 DK 2248815T3
- Authority
- DK
- Denmark
- Prior art keywords
- pyrazolo
- dimethyl
- substituted
- pyrimidine
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (14)
1
I
1. Substituerede 3-arylsulfonyl-pyrazolo[l,5-a]pyrimidiner med den almene formel 1 eller farmaceutisk acceptable salte og/eller hydrater deraf, hvor: Ar betegner eventuelt substitueret C6-C14 aryl; R1, R2 og R3 uafhængigt af hinanden betegner hydrogen, C1-C3 alkyl eller phenyl; R4 betegner hydrogen, C1-C5 al kyl, substitueret hydroxygruppe eller substitueret sulfanylgruppe; og forbindelser med formel 1(2), 1(3) og 1(4)
- \—,» - \—Λ
rneu unuiageise ar: 5.7- dimethyl-3-(phenylsulfonyl)pyrazolo[l,5-a]pyrimidin; 5.7- dimethyl-3-tosylpyrazolo[l,5-a]pyrimidin. 2
2. Forbindelser ifølge krav 1 der betegner substituerede 3-arylsulfonyl-5,7-dimethyl-pyrazolo[l,5-a]pyrimidiner med den almene formel 1.1 eller farmaceutisk acceptable salte og/eller hydrater deraf
5 1.1 hvor: R4 er som defineret i krav 1; R5 betegner en eller to eventuelt identiske substituenter valgt fra hydrogen, C1-C4 alkyl, trifluormethyl, alkoxygruppe, substitueret aminogruppe eller halogen.
3. Forbindelser ifølge krav 2 der betegner 5,7-dimethyl-2-(2-hydroxyethyl)-3- phenylsulfonyl-pyrazolo[l,5-a]pyrimidin 1.1(2), 5,7-dimethyl-3-(4-fluorphenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(3), 5,7-dimethyl-2-(2-hydroxyethyl)-3-(4-fluorphenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(4), 5,7-dimethyl-2-methylsulfanyl-3-phenylsulphonylpyrazolo[l,5-a]pyrimidin 1.1 (5), 5,7-dimethyl-3-phenylsulfonyl-2-5 ethylsulfanyl-pyrazolo[l,5-a]pyrimidin 1.1(6), 5,7-dimethyl-2-methylsulfanyl-3-(4-fluorphenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(7), 5,7-dimethyl-2-ethylsulfanyl-3-(4-fluorphenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(8); 5,7-dimethyl-2-methylsulfanyl-3-(3-fluorphenylsulfonyl) pyrazolo[l,5-a]pyrimidin 1.1(9), 5,7-dimethyl-2-ethylsulfanyl-3-(3-fluorphenylsulfonyl)pyrazolo[l,5-a]pyrimidin 1.1(10), 5,7-dimethyl-2-methylsulfanyl-3-D (3-chlorophenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(11), 5,7-dimethyl-2-ethylsulfanyl-3-(3-chlorophenylsulfonyl)-pyrazolo[l,5-a]pyrimidin 1.1(12) eller farmaceutisk acceptable salte og/eller hydrater deraf
3 nr. Λ nr
4. Forbindelser ifølge krav 1 valgt fra gruppen bestående af ρμ
1(1 1(3 1(5 4
5 6
5. Fremgangsmåde til fremstillingen af forbindelser ifølge et hvilket som helst af kravene 1 - 4 ved interaktion af 3-amino-4-sulfonyl-2H-pyrazoler med den almene formel 2 med tilsvarende β-diketoner med den almene formel 3 med efterfølgende isolering eller arlcl/illelce af mal/finncnrnHi il/toma
hvor: R1, R2, R3, R4 og R5 alle er som defineret i de foregående krav.
6. Substituerede 3-arylsulfonyl-pyrazolo[l,5-a]pyrimidiner med den almene formel 1
Ar betegner eventuelt substituerede C5-Ci4 aryl eller eventuelt substitueret heterocyclyl der er en aromatisk mono- eller polycyklisk system med 3-10 carbonatomer, hvor ét eller flere carbonatomer er substitueret med et heteroatom valgt fra N, O eller S; R1, R2 og R3 uafhængigt af hinanden betegner hydrogen, C1-C3 alkyl eller phenyl; 7 R4 betegner hydrogen, C1-C5 al kyl, substitueret hydroxygruppe eller substitueret sulfanylgruppe; eller farmaceutisk acceptable salte og/eller hydrater deraf til anvendelse som et medikament.
7. Forbindelser ifølge krav 6, hvor forbindelserne er valgt fra forbindelserne ifølge et hvilket som helst af kravene 1 - 4 og forbindelser med formel 1.1(1)
8. Farmaceutisk sammensætning omfattende en farmaceutisk effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1-4 eller farmaceutisk acceptable salte og/eller hydrater deraf.
9. Farmaceutisk sammensætning ifølge krav 8 yderligere omfattende et inert fyldstof 5 og/eller fortynder.
10. Medikament omfattende mindst én forbindelse ifølge et hvilket som helst af kravene 1 - 4 eller farmaceutisk acceptable salte og/eller hydrater deraf eller farmaceutisk sammensætning ifølge et hvilket som helst af kravene 8 or 9. D
11. Medikamentet ifølge krav 10 i form af tabletter, kapsler, eller injektioner anbragt i en farmaceutisk acceptabel pakning.
12. Medikamentet ifølge krav 10 eller 11 der er egnet til profylakse og behandling af 5 patologiske tilstande af CNS- og CNS-sygdomspatogenese der er forbundet med forstyrrelse af serotonin 5-HT6-receptoraktivering.
13. Substituerede 3-arylsulfonyl-pyrazolo[l,5-a]pyrimidiner med den almene formel 1 eller farmaceutisk acceptable salte og/eller hydrater deraf 8
Ar betegner eventuelt substituerede C6-C14 aryl eller eventuelt substitueret heterocyclyl der er en aromatisk mono- eller polycyklisk system med 3-10 5 carbonatomer, hvor ét eller flere carbonatomer er substitueret med et heteroatom valgt fra N, O eller S; R1, R2 og R3 uafhængigt af hinanden betegner hydrogen, C1-C3 alkyl eller phenyl; R4 betegner hydrogen, C1-C5 al kyl, substitueret hydroxygruppe eller substitueret sulfanylgruppe; LO eller farmaceutisk acceptable salte og/eller hydrater deraf til anvendelse i profylakse og behandling af patologiske tilstande af CNS- og CNS-sygdomme, patogenese der er forbundet med forstyrrelse af serotonin 5-HT6-receptoraktivering hos mennesker og dyr. L5 14. Forbindelser ifølge krav 13, hvor forbindelserne er valgt fra forbindelserne ifølge et hvilket som helst af kravene 1 - 4 og forbindelser med formel i. Hi;
15. Forbindelser ifølge krav 13 or 14, hvor sygdommen er valgt fra neurologiske 20 forstyrrelser, neurodegenerative og kognitive sygdomme hos mennesker og dyr, Alzheimer's sygdom, Huntington's sygdom, psykiske forstyrrelser, skizofreni, hypoxi-iskæmi, hypoglykæmi, konvulsive tilstande, hjerneskader, latyrisme, amyotrof lateral sklerose, fedme eller insult hos mennesker og dyr. 25
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2008102154/04A RU2369600C1 (ru) | 2008-01-24 | 2008-01-24 | ЗАМЕЩЕННЫЕ 4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ5-HT6 РЕЦЕПТОРОВ, АКТИВНЫЙ КОМПОНЕНТ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ЛЕКАРСТВЕННОЕ СРЕДСТВО И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
PCT/IB2009/050270 WO2009093206A2 (ru) | 2008-01-24 | 2009-01-23 | 3-CУЛЬФOHИЛ-ПИPAЗOЛO[1,5-a]ПИPИMИДИHЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2248815T3 true DK2248815T3 (da) | 2014-11-17 |
Family
ID=40901496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09703835.0T DK2248815T3 (da) | 2008-01-24 | 2009-01-23 | 3-sulfonyl-pyrazolo[1,5-a]pyrimidiner/antagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelsen deraf |
Country Status (10)
Country | Link |
---|---|
US (1) | US8552005B2 (da) |
EP (1) | EP2248815B1 (da) |
JP (1) | JP5690594B2 (da) |
KR (1) | KR101526930B1 (da) |
CA (1) | CA2749742C (da) |
DK (1) | DK2248815T3 (da) |
EA (1) | EA017817B1 (da) |
RU (1) | RU2369600C1 (da) |
UA (4) | UA100137C2 (da) |
WO (1) | WO2009093206A2 (da) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3020719B1 (en) * | 2008-10-06 | 2017-09-20 | Alla Chem, LLC. | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof and methods for the production and use thereof |
US10864191B2 (en) | 2016-05-11 | 2020-12-15 | H. Lundbeck A/S | 5-HT6 receptor antagonists for use in the treatment of Alzheimer's disease with apathy as comorbidity |
AU2017328614B2 (en) * | 2016-09-19 | 2022-01-13 | Bayer Aktiengesellschaft | Pyrazolo [1,5-a]pyridine derivatives and their use as pesticides |
PL3630098T3 (pl) | 2017-05-24 | 2021-09-06 | H. Lundbeck A/S | Połączenie antagonisty receptora 5-ht6 i inhibitora acetylocholinoesterazy do zastosowania w leczeniu choroby alzheimera w subpopulacji pacjentów posiadających allele apoe4 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09143181A (ja) * | 1995-09-22 | 1997-06-03 | Takeda Chem Ind Ltd | 新規トリアゾール系化合物、その製造法、中間体および農薬 |
AU7001396A (en) * | 1995-09-22 | 1997-04-09 | Takeda Chemical Industries Ltd. | Triazole compounds, their production and use |
US6194410B1 (en) * | 1998-03-11 | 2001-02-27 | Hoffman-La Roche Inc. | Pyrazolopyrimidine and pyrazolines and process for preparation thereof |
AU2002364035A1 (en) | 2001-12-28 | 2003-07-24 | Bayer Pharmaceuticals Corporation | 4-sulfide / sulfoxide / sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor |
WO2003080608A2 (en) * | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
JP2004277337A (ja) * | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ[1,5−a]ピリミジン誘導体 |
AR056876A1 (es) * | 2005-10-21 | 2007-10-31 | Tanabe Seiyaku Co | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares |
JP4847275B2 (ja) * | 2005-10-21 | 2011-12-28 | 田辺三菱製薬株式会社 | ピラゾロ[1,5−a]ピリミジン化合物 |
CA2709784A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
-
2008
- 2008-01-24 RU RU2008102154/04A patent/RU2369600C1/ru not_active IP Right Cessation
-
2009
- 2009-01-23 US US12/812,728 patent/US8552005B2/en active Active
- 2009-01-23 EA EA201001179A patent/EA017817B1/ru not_active IP Right Cessation
- 2009-01-23 EP EP09703835.0A patent/EP2248815B1/en not_active Not-in-force
- 2009-01-23 CA CA2749742A patent/CA2749742C/en not_active Expired - Fee Related
- 2009-01-23 WO PCT/IB2009/050270 patent/WO2009093206A2/ru active Application Filing
- 2009-01-23 JP JP2010543609A patent/JP5690594B2/ja not_active Expired - Fee Related
- 2009-01-23 DK DK09703835.0T patent/DK2248815T3/da active
- 2009-01-23 UA UAA201009959A patent/UA100137C2/ru unknown
- 2009-01-23 UA UAA201009961A patent/UA100138C2/ru unknown
- 2009-01-23 KR KR1020107018828A patent/KR101526930B1/ko active IP Right Grant
- 2009-01-23 UA UAA201009960A patent/UA101643C2/ru unknown
- 2009-01-23 UA UAA201009958A patent/UA102087C2/ru unknown
Also Published As
Publication number | Publication date |
---|---|
EP2248815A2 (en) | 2010-11-10 |
UA100138C2 (ru) | 2012-11-26 |
WO2009093206A2 (ru) | 2009-07-30 |
EA201001179A1 (ru) | 2011-02-28 |
RU2369600C1 (ru) | 2009-10-10 |
RU2008102154A (ru) | 2009-07-27 |
UA102087C2 (en) | 2013-06-10 |
JP5690594B2 (ja) | 2015-03-25 |
EP2248815B1 (en) | 2014-09-24 |
CA2749742A1 (en) | 2009-07-30 |
KR20100137428A (ko) | 2010-12-30 |
EA017817B1 (ru) | 2013-03-29 |
UA100137C2 (en) | 2012-11-26 |
JP2011510061A (ja) | 2011-03-31 |
KR101526930B1 (ko) | 2015-06-08 |
US8552005B2 (en) | 2013-10-08 |
EP2248815A4 (en) | 2012-02-15 |
CA2749742C (en) | 2016-04-26 |
UA101643C2 (en) | 2013-04-25 |
US20100331347A1 (en) | 2010-12-30 |
WO2009093206A3 (ru) | 2009-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2248816B1 (en) | 2-ALKYLAMINO-3-ARYLSULFONYL-CYCLOALCANO [e OR d] PYRAZOLO[1,5-A]PYRIMIDINES AS ANTAGONISTS OF SEROTONIN 5-HT6 RECEPTORS, METHODS FOR THE PRODUCTION AND THE USE THEREOF | |
US8629154B2 (en) | Substituted cycloalcano[e and d] pyrazolo [1,5-a]pyrimidines/antagonists of serotonin 5-HT6 receptors and methods for production and the use thereof | |
DK2248815T3 (da) | 3-sulfonyl-pyrazolo[1,5-a]pyrimidiner/antagonister af serotonin 5-ht6-receptorer, fremgangsmåder til fremstillingen og anvendelsen deraf | |
US8829009B2 (en) | Substituted 2-amino-3-(sulfonyl)pyrazolo[1,5-a]pyrimidines - serotonin 5-HT6 receptor antagonists, method for use thereof | |
KR101651933B1 (ko) | 세로토닌 5-ht6 수용체의 2-아미노-3-설포닐-테트라하이드로-피라졸로[1,5-a]피리도-피리미딘 길항제, 이의 제조방법 및 이의 용도 | |
EP3020719B1 (en) | Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-ht6 receptor antagonists and methods for the production and use thereof and methods for the production and use thereof | |
RU2393158C1 (ru) | ЗАМЕЩЕННЫЕ 3-АРИЛСУЛЬФОНИЛ-ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
RU2376291C1 (ru) | ЗАМЕЩЕННЫЕ 3,5-ДИАМИНО-4-СУЛЬФОНИЛ-ПИРАЗОЛЫ И 2-АМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
RU2374249C1 (ru) | ЗАМЕЩЕННЫЕ ЦИКЛОАЛКАНО[е ИЛИ d]ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ - АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-НТ6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |